Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial

Weight Loss Drugs

Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy
Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy
Super Bowl Commercials 2026: Complete List Of Ads, The Companies Behind Them And Who Won Over Fans
Super Bowl Commercials 2026: Complete List Of Ads, The Companies Behind Them And Who Won Over Fans
Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic
Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic
Super Bowl Commercials 2026: Complete List Of Ads, The Companies Behind Them And Who Won Over Fans
Super Bowl Commercials 2026: Complete List Of Ads, The Companies Behind Them And Who Won Over Fans
Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic
Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic
Musk In The Rearview: Linda Yaccarino Puts X Behind Her To Become Tom Brady's Boss
Musk In The Rearview: Linda Yaccarino Puts X Behind Her To Become Tom Brady's Boss
Novo Nordisk, Starfighters Space, D-Wave Quantum, Sidus Space And ZIM Integrated Shipping: Why These 5 Stocks Are On Investors' Radars Today
Novo Nordisk, Starfighters Space, D-Wave Quantum, Sidus Space And ZIM Integrated Shipping: Why These 5 Stocks Are On Investors' Radars Today

Weight Loss Drugs Recent News

FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims
FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims
The FDA finds Eli Lilly's video on Zepbound and Mounjaro misleading, citing omissions of serious risks.
Ozempic Is The New Botox And Big Pharma Is Printing Billions
Ozempic Is The New Botox And Big Pharma Is Printing Billions
Ozempic and Zepbound have helped Novo Nordisk and Eli Lilly achieve a combined market cap topping $900 billion.
From Elon's X To Weight-Loss Rx: Linda Yaccarino's 'Milestone Day' With Aon
From Elon's X To Weight-Loss Rx: Linda Yaccarino's 'Milestone Day' With Aon
A telehealth company led by former X CEO Linda Yaccarino announced major news Monday.
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential.
McDonald's Just Got Hammered By Weight-Loss Drugs — Twice
McDonald's Just Got Hammered By Weight-Loss Drugs — Twice
McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned.
Veru's Enobosarm Shows Muscle In Wegovy Combo Trial
Veru's Enobosarm Shows Muscle In Wegovy Combo Trial
Veru reports strong safety and efficacy for enobosarm added to semaglutide, showing reduced functional decline and muscle loss in older adults.
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.
Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?
Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?
Elon Musk sparked conversation about weight-loss drugs and side effects with a Christmas social media post.
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market.
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's what you need to know.
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains (CORRECTED)
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains (CORRECTED)
Eli Lilly reports Q3 earnings on Wednesday. Stock up 58% in past year, potential to split to attract investors in growing weight loss market.
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Viking Therapeutics (VKTX) set to report Q3 earnings amid high expectations, thanks to promising weight-loss drug candidate. Stock up 240% YTD.
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected.
Weight-Loss Giant Novo Nordisk Tumbles To 200-Day Average Support: 'Weakness Could Be Buying Opportunity,' Analyst Says
Weight-Loss Giant Novo Nordisk Tumbles To 200-Day Average Support: 'Weakness Could Be Buying Opportunity,' Analyst Says
Shares of Novo Nordisk are down 6% after Q2 results fell short of expectations; weight-loss drug sales disappoint.
What's Going On With HIMS Shares Today?
What's Going On With HIMS Shares Today?
Hims & Hers Health experienced a significant decline in its stock price on Thursday. Here's what you need to know.
Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
Liraglutide shows promise in slowing cognitive decline in Alzheimer's patients, reducing brain volume loss and offering neuroprotective benefits, according to a Phase 2b clinical trial presented at AAIC 2024.
Walt Disney, Eli Lilly, AST SpaceMobile, DexCom, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Walt Disney, Eli Lilly, AST SpaceMobile, DexCom, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Thursday, major U.S. indices showed mixed results. The Dow Jones Industrial Average increased by 0.2% to 39,935.07.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved